What's Next: Staar Surgical's Earnings Preview
Staar Surgical (NASDAQ:STAA) will release its quarterly earnings report on Tuesday, 2026-03-03. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Staar Surgical to report an earnings per share (EPS) of $0.11.
Staar Surgical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.01, leading to a 5.47% increase in the share price on the subsequent day.
Here's a look at Staar Surgical's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.17 | -0.60 | 0.11 | 0.00 |
| EPS Actual | 0.18 | -0.34 | -0.64 | -0.69 |
| Price Change % | 5.47 | 0.19 | 0.46 | -24.68 |
Performance of Staar Surgical Shares
Shares of Staar Surgical were trading at $19.9 as of February 27. Over the last 52-week period, shares are up 5.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
All You Need to Know About Staar Surgical
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Understanding the Numbers: Staar Surgical's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 6.93%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Staar Surgical's net margin excels beyond industry benchmarks, reaching 9.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.99%, the company showcases efficient use of assets and strong financial health.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
To track all earnings releases for Staar Surgical visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.